- Home
- LSBK vs CNTB Comparison
LSBK vs CNTB Comparison
Compare LSBK & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSBK | CNTB |
|---|---|---|
| Founded | 1891 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 135.7M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LSBK | CNTB |
|---|---|---|
| Price | $16.99 | $2.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 8.5K | ★ 605.8K |
| Earning Date | 04-22-2026 | 08-13-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 49.23 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $65.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.50 | $1.23 |
| 52 Week High | $17.96 | $3.82 |
Technical Indicators
Market Signals| Indicator | LSBK | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 58.39 |
| Support Level | $16.64 | $2.30 |
| Resistance Level | $17.76 | $2.74 |
| Average True Range (ATR) | 0.45 | 0.22 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 29.17 | 65.93 |
Price Performance
Historical ComparisonAbout LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.